Sino Biopharmaceutical (1177) Stock Statistics & Valuation Metrics

Sino Biopharmaceutical has a market cap or net worth of $89.24B. The enterprise value is HK$85.98B.

Sino Biopharmaceutical has 18,760,717,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sino Biopharmaceutical’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 10.63%.

The current PE Ratio of Sino Biopharmaceutical is 28.65. Sino Biopharmaceutical’s PEG ratio is -0.23.

In the last 12 months, Sino Biopharmaceutical had revenue of 28.87B and earned 3.50B in profits. Earnings per share was 0.10.

In the last 12 months, operating cash flow was 3.08B and capital expenditures -407.50M, giving a free cash flow of 2.67B billion.

Sino Biopharmaceutical pays an annual dividend of HK$0.314, resulting in a dividend yield of 12.58%

Sino Biopharmaceutical upcoming earnings date is Aug 28, 2025, TBA Not Confirmed.

Sino Biopharmaceutical as a current ratio of 1.26, with Debt / Equity ratio of 47.00%

In the past 12 months, Sino Biopharmaceutical has paid 492.92M in taxes.

Sino Biopharmaceutical EV to EBITDA ratio is 16.45, with an EV/FCF ratio of 0.00.

Sino Biopharmaceutical has $14.60B in cash and marketable securities with ¥9.78B in debt, giving a net cash position of -$4.81B billion.

Gross margin is 79.86%, with operating margin of 21.76%, and net profit margin of 12.12%.

The average price target for Sino Biopharmaceutical is $6.04, which is 11.43% higher than the current price. The consensus rating is Moderate Buy